Elafibranor Granted Priority Review for Primary Biliary Chol

Elafibranor Granted Priority Review for Primary Biliary Cholangitis

The FDA has accepted for Priority Review the NDA for elafibranor for the second-line treatment of primary biliary cholangitis.

Related Keywords

Christelle Huguet , Drug Administration , Head Of Research Development , Priority Review , New Drug Application , Itch Numeric Rating Scale ,

© 2025 Vimarsana